Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest drug discovery Stories

2014-04-08 08:29:54

IRVINE, Calif., April 8, 2014 /PRNewswire/ -- Sideromics LLC, a pharmaceutical company specializing in the development of novel antimicrobial compounds, announced today that the company has successfully completed a Type B pre-investigational new drug (PIND) meeting with the U.S. Food and Drug Administration (FDA) Division of Anti-Infective Products (DAIP). The purpose of the meeting was to obtain FDA concurrence on the nonclinical, clinical, and regulatory pathway for the development of...

2014-04-07 08:30:25

Presentation "DNA Damage Response and Tumor Metastasis" to be Presented April 7, 2014 at ESTRO 33, the Premier European Event in Radiation Oncology BIRMINGHAM, Ala., April 7, 2014 /PRNewswire/ -- Southern Research Institute today announced that the Institute's translational radiation oncology research program in the Drug Discovery Division has been invited to present at a symposium during the European Society of Radiotherapy and Oncology (ESTRO) 33(rd) annual meeting being held in...

2014-04-07 08:23:40

IRVINE, Calif., April 7, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with Brazilian Biosciences National Laboratory (LNBio) to evaluate ChromaDex's natural product libraries. ChromaDex and LNBio are...

2014-04-04 23:34:34

Innovative Adaptive Designs Increase Trial Flexibility and Efficiency, Generating Significant Ethical and Economic Advantages Reston, Virginia (PRWEB) April 03, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, will present emerging strategies for using adaptive trial designs to improve the success...

2014-04-04 23:34:00

Experts to Discuss How the Revolutionary Technology is Used Today and Can Reshape the Future WASHINGTON (PRWEB) April 03, 2014 Experts of 3D printing will discuss how the innovation could change drug discovery and health delivery, at the DIA 2014 50th Annual Meeting in San Diego. “Health Care’s Revolutionary Printing Press? 3D Printing – Blue Sky and Regulatory Path”, to be held on June 17 at 10:30 a.m. at the San Diego Convention Center, will identify the uses of 3D printing, the...

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...

2014-04-04 23:03:51

The major factors driving the growth of the high content screening (HCS) market include the need for determining the level of toxicity in the early stages of drug discovery pipeline, government support for cell-based research, and the introduction of enhanced informatics solutions and improved image analysis instruments. http://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html (PRWEB) April 04, 2014 The “High Content Screening Market by Instruments...

2014-04-04 08:25:09

REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9(th). Presentation details are as follows: 13(th) Annual Needham Healthcare Conference Date: Wednesday,...

2014-04-03 08:29:00

- More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational...

2014-04-02 23:32:53

Cambridge Biomedical Inc. announces that their Chief Operating Officer, Dr. John Reddington, will be attending the 4th annual World Orphan Drug Congress in Washington D.C. April 23-25th, 2014 Boston, MA (PRWEB) April 02, 2014 Cambridge Biomedical’s experience with bioanalytical assay development, optimization, validation and diagnostic testing has proved instrumental in assisting biotechnology and pharmaceutical companies that are focusing on therapies for orphan and ultra-rare disease...